Royalty Pharma (RPRX) Free Cash Flow (2019 - 2026)

Royalty Pharma (RPRX) has 8 years of Free Cash Flow data on file, last reported at $265.9 million in Q1 2026.

• For the quarter ending Q1 2026, Free Cash Flow fell 55.32% year-over-year to $265.9 million; the trailing twelve-month figure through Mar 2026 stood at $462.9 million (up 65.48% YoY), and the FY2025 full-year result was $792.1 million, up 200.85% from the prior year.
• Free Cash Flow rose to $265.9 million in Q1 2026, from $93.5 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of $595.0 million in Q1 2025 to a low of -$777.5 million in Q3 2022.
• A 5-year average of $152.7 million and a median of $265.9 million in 2026 frame the typical range for Free Cash Flow.
• Across the five-year window, Free Cash Flow jumped 1898.2% in 2022 and tumbled 501.15% in 2024, its largest moves.
• Tracing RPRX's Free Cash Flow over 5 years: stood at $319.7 million in 2022, then plunged by 171.82% to -$229.6 million in 2023, then surged by 207.18% to $246.1 million in 2024, then slumped by 62.02% to $93.5 million in 2025, then surged by 184.46% to $265.9 million in 2026.
• Business Quant data shows RPRX's Free Cash Flow at $265.9 million in Q1 2026, $93.5 million in Q4 2025, and -$259.3 million in Q3 2025.